Abnormal expression of glucose regulated protein 78 in glioma and its clinical significance
10.3760/cma.j.cn115455-20200731-00988
- VernacularTitle:葡萄糖调节蛋白78在神经胶质瘤中的异常表达及临床意义
- Author:
Xiaojun ZHANG
1
;
Yisong ZHANG
;
Zhong WANG
;
Ruijian ZHANG
;
Wei SUN
Author Information
1. 内蒙古自治区人民医院神经外科，呼和浩特 010017
- Keywords:
Glucose regulatory protein 78;
Glioma;
Endoplasmic reticulum stressation;
Signal pathway
- From:
Chinese Journal of Postgraduates of Medicine
2021;44(7):591-595
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the expression of glucose regulated protein 78 (GRP78) in glioma and its clinical value in evaluating clinical prognosis.Methods:A total of 163 patients with glioma who were surgically removed and confirmed after surgery in the People′s Hospital of Inner Mongolia Autonomous Region were collected from March 2012 to October 2015. Immunohistochemical staining was used to observe the expression of GRP78 in patients with different WHO grades of glioma. Chi square test was used to compare the expression of GRP78 in glioma patients with different age, gender and WHO grade. Whether COX regression analysis GRP78 can be used as an independent prognostic indicator was investigated. Time series test and Kaplan Meier analysis were used to analyze the survival time of patients with different GRP78 expression levels.Results:The expression of GRP78 was up-regulated in glioma, and the patients with high expression of GRP78 (positive expression/strongly positive expression) were more common in stage Ⅲ/Ⅳ than in stage Ⅰ/Ⅱ. The expression of GRP78 was not statistically significant in different age and gender groups ( P>0.05), but was statistically significant in different WHO stages ( P<0.01). GRP78 was an independent prognostic factor for glioma ( P = 0.045). The median survival time of patients with glioma was 28 months (95% CI 37.594 to 47.046), of which the survival time of patients with high expression of GRP78 was 15 months (95% CI 12.922 to 40.801); the survival time of patients with low expression of GRP78 was 35 months (95% CI 39.807 to 51.352), and the difference was statistically significant ( P<0.01). The survival time of patients with high expression of GRP78 was significantly shorter than that of patients with low expression of GRP78 ( χ2 = 13.588, P<0.01). Conclusions:The expression level of GRP78 in glioma is significantly increased; high expression of GRP78 is more common in Ⅲ/Ⅳ glioma, and GRP78 can be used as an effective index to evaluate the poor prognosis of glioma.
